How Mineralocorticoid Receptor Antagonists (MRAs) Work
MRAs work by blocking mineralocorticoid receptors in the kidneys and cardiovascular system, preventing aldosterone from binding and thereby reducing sodium reabsorption, potassium excretion, and end-organ damage including cardiac fibrosis and vascular dysfunction 1.
Mechanism of Action
Renal Effects
MRAs competitively inhibit aldosterone binding to mineralocorticoid receptors (MRs) in the distal convoluted nephron 1. When aldosterone normally binds to these receptors, it increases expression and activation of epithelial sodium channels (ENaCs), leading to:
- Increased sodium reabsorption (causing volume expansion and hypertension)
- Increased potassium excretion (causing hypokalemia)
- ENaC is a major regulator of sodium excretion in the renin-angiotensin-aldosterone system (RAAS) feedback loop 1
By blocking MRs, these drugs reverse this process—reducing sodium retention and preserving potassium.
Cardiovascular and Anti-Fibrotic Effects
Beyond blood pressure control, MRAs provide critical end-organ protection 1:
- Reduce cardiac fibrosis and left ventricular hypertrophy
- Prevent arterial stiffening and vascular dysfunction (ENaCs are also expressed in cardiovascular tissue where their activation promotes fibrosis)
- Attenuate tubulointerstitial fibrosis and microalbuminuria
- Anti-inflammatory effects that reduce progressive kidney and cardiac damage 2, 3
This explains why MRAs reduce mortality and heart failure hospitalizations beyond their antihypertensive effects alone 4, 5.
Types of MRAs
Steroidal MRAs (e.g., spironolactone, eplerenone)
- Remain the foundational first-line therapy 1
- Spironolactone has anti-androgen effects (gynecomastia, breast pain in women) due to cross-reactivity with progesterone and androgen receptors 1
- Widely available and inexpensive 1
Non-Steroidal MRAs (e.g., finerenone)
- Greater receptor selectivity with fewer hormonal side effects 2, 6
- Demonstrated cardiorenal benefits in high-risk populations including diabetic kidney disease and non-diabetic proteinuric CKD 6, 3
- Better safety profile regarding hyperkalemia risk compared to steroidal agents 6
Clinical Implications
The 2025 Endocrine Society guidelines recommend MRAs over ENaC inhibitors (amiloride, triamterene) as first-line medical therapy for primary aldosteronism 1, though direct head-to-head trials are lacking. Spironolactone remains first-line unless contraindicated (hyperkalemia, advanced renal impairment, pregnancy) or not tolerated due to hormonal side effects 1.
Common Pitfalls
- Hyperkalemia remains the primary safety concern requiring monitoring, particularly when combined with RAAS inhibitors or SGLT2 inhibitors 3
- MRAs are significantly underutilized in heart failure despite mortality benefits 4, 5
- Delayed initiation and suboptimal dosing are common in real-world practice 5
The multi-level protective effects—blocking both hemodynamic (sodium/volume) and direct tissue injury pathways—make MRAs uniquely effective in conditions with aldosterone excess or MR overactivation 2, 3.